Clinical Trial Update: Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of sorafenib and pegylated interferon α2b in stage IV metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Nexavar (Sorafenib)
• Pegylated Interferon α-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: University Hospital Schleswig-Holstein | Conditions: Melanoma | Phase 2 | Status: COMPLETED